NEW YORK (GenomeWeb) – Germany-based LifeCodexx said today it has received CE marking for analysis software for a new noninvasive prenatal test for fetal trisomy 21 that is based on methylation-specific quantitative PCR.

The software, PrenaTest BioIT, is now cleared for the analysis of data from both LifeCodexx's existing next-generation sequencing-based PrenaTest and from its new methylation-specific qPCR-based qNIPT assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.